TRANSFORM-HF Ancillary Mechanistic Study

Completed

Conditions studied: Heart Failure

In brief

Patients with heart failure are frequently treated with diuretics, including furosemide and torsemide, but it is not known if one is better than the other. The TRANSFORM-HF trial is studying if torsemide is superior than furosemide for reducing the endpoint of death or hospitalization, but is not designed to study why. This ancillary study seeks to measure proteins in the blood and urine to help explain the underlying mechanism for why patients who take one of these diuretics may have better outcomes than patients who take the other.

Key facts

Study ID

NCT04702958

Run by

Inova Health Care Services

People needed

150

Starts

2020-12-10

Expected to finish

2023-05-30

Last updated by the study team

2023-10-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participation in the TRANSFORM-HF trial or prescription of Torsemide or Furosemide
• Willing to provide blood and urine sample at enrollment and follow-up

You may not qualify if…

• Inability or unwillingness to comply with the study requirements

Where it is running

• Yale University School of Medicine — New Haven, Connecticut, United States
• Ochsner Clinic Foundation — New Orleans, Louisiana, United States
• Baltimore VA — Baltimore, Maryland, United States
• University of Minnesota — Minneapolis, Minnesota, United States
• Northwell Health — Manhasset, New York, United States
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
• Duke University Hospital — Durham, North Carolina, United States
• Inova Health System — Falls Church, Virginia, United States
• Sentara Norfolk — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.